Enrolling

A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

I7S-MC-HBEO -

The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety.

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
50 - 80 years
Conditions the trial is for
Alzheimer Disease
What the trial is testing?
Mevidalen
Could I receive a Placebo?
Yes
Enrollment Goal
300
Trial Dates
Aug 26, 2024 - Jan 2026
How long will I be in the trial?
The study is expected to last approximately 26 weeks and may include up to 14 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have Alzheimer’s disease (AD) with gradual and progressive decline in memory function for greater than or equal to 6 months

  • Have a reliable study partner who will participate in the study to support the participant

  • Be males with partners of childbearing potential must agree to abide with provided contraception guidance

Participants Must Not:

  • Have prior central nervous system or psychiatric disease other than AD

  • Have history of cardiovascular or liver disorders

  • Be currently enrolled or intend to enroll in a clinical trial of another investigational product

  • Have suicidal tendencies

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources